[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559992":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":32,"locations":40,"responsibleParty":59,"collaborators":10,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":10,"eligibilityCriteria":66,"healthyVolunteers":63,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Medical University of Gdansk","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"25(OH)D \u003C 30 ng\u002FmL",null,"Dialysed patients with vitamin D level (25(OH)D) \\\u003C 30 ng\u002FmL administered cholecalciferol",[13],"Drug: Cholecalciferol",{"label":15,"type":10,"description":16,"interventionNames":17},"25(OH)D 30 - 49.9 ng\u002FmL","Dialysed patients with vitamin D level (25(OH)D) 30-49.9 ng\u002FmL administered cholecalciferol",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"25(OH)D 50-80 ng\u002FmL","Dialysed patients with vitamin D level (25(OH)D) 50-80 ng\u002FmL administered cholecalciferol",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"DRUG","Cholecalciferol","The patients with vitamin D (25(OH)D) levels \\\u003C 30 ng\u002FmL, and 30-50 ng\u002Fml will recieve a dose of cholecalciferol at 70,000 IU per week (20,000 IU + 20,000 IU + 30,000 IU per week).\n\nIn the patients with 25(OH)D levels 50-80 ng\u002FmL the dose of cholecalciferol will be adjusted to avoid exceeding the upper limit of the laboratory norm.",[15,19,9],[29],{"name":30,"affiliation":5,"role":31},"Leszek Tylicki, Prof.","PRINCIPAL_INVESTIGATOR",[33,37],{"name":30,"role":34,"phone":35,"phoneExt":10,"email":36},"CONTACT","+ 48 58 584 47 00","leszek.tylicki@gumed.edu.pl",{"name":38,"role":34,"phone":10,"phoneExt":10,"email":39},"Agnieszka Tarasewicz, MD; PhD","ataras@gumed.edu.pl",[41],{"facility":5,"status":42,"city":43,"state":10,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Gdansk","80-211","Poland","PL",{"type":48,"coordinates":49},"Point",[50,51],18.64912,54.35227,{"lat":51,"lon":50},[54,57],{"name":55,"role":34,"phone":56,"phoneExt":10,"email":36},"Tylcki Leszek, Prof.","+48 58 584 47 07",{"name":58,"role":34,"phone":56,"phoneExt":10,"email":39},"Agnieszka Tarasewicz, Md, PhD",{"type":60,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100559992","vitamin-d-in-dialysis-patients---diagnostic-and-therapeutic-management-100559992",false,"NCT06571344","Vitamin D in Dialysis Patients - Diagnostic and Therapeutic Management","Inclusion Criteria:\n\n* CKD stage 5,dialysed patients with vitamin D deficiency or insufficiency (level of 25(OH)D \\\u003C 30 ng\u002FmL)\n\nExclusion Criteria:\n\n* dialysis time of less than 3 months\n* inadequately controled secondary hyperparathyroidism (iPTH\\>800pg\u002FmL)\n* treatment with calcimimetics\n* treatment with active forms of vitamin D3,\n* parathyroidectomy\n* bilateral nephrectomy\n* treatment with corticosteroids\n* lack of consent to take part in the study.","ALL","18 Years",{"count":70,"type":71},160,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the effects of cholecalciferol administration, according to guidelines for the general population, on laboratory parameters of Chronic Kidney Disease-Mineral and Bone Disorder in dialysis patients, depending of the attained levels of vitamin D (25OH)D).\n\nThe main question it aims to answer is:\n\nHow does cholecalciferol affect calcium and phosphate metabolism parameters depending on the achieved levels of 25(OH)D?\n\nParticipants taking cholecalciferol as part of their regular medical care for CKD-MBD will have the laboratory result parameters observed for up to 4 years.",[75],"Vitamin D Deficiency Due to Chronic Kidney Disease",[77,78,79,80,81,82,83,84],"vitamin D","cholecalciferol","25-hydroxycholecalciferol","parathyroid hormone","FGF23","GDF15","chronic kidney disease-mineral and bone disorder","dialysis","2024-08-23",{"date":87,"type":88},"2024-08-26","ACTUAL",{"date":90,"type":88},"2022-11-01",{"date":92,"type":71},"2026-12-31",{"name":5,"class":6},1]